The phase IIIb/IV SPINART trial showed that after 3 years of follow-up, participants with established arthropathy on FVIII prophylaxis experienced a 94% reduction in number of bleeds; however, magnetic resonance imaging–assessed hemophilic arthropathy remained unchanged over time [38]. This evidence concerns the gene F8 and arthropathy.